As a winner in the 2015 “Innovation Project” organised by the Association of Pharmaceutical Companies in Greece, Amyndas enjoys significant exposure in the local press and media in Greece. The science news source from two Greek Sunday newspapers, Kathimerini (November 16, 2014) and Makedonia (November 23, 2014) posted an informative profile of Amyndas, describing the company’s novel technology licensed from the Universiy of Penn, the wide range of potential therapeutic applications and the profound impact that these new therapies can have for patients and health care systems internationally. The articles (in Greek) created significant reader’s interest and can be accessed at: http://www.kathimerini.com.cy/index.php?pageaction=kat&modid=1&artid=189465&show=Y (newspaper Kathimerini) and http://www.makthes.gr/news/reportage/129900/ (newspaper Makedonia).
The “Innovation Project” is an open call competition organized by the Association of Pharmaceutical Companies in Greece, designed for small companies, spin-offs, entrepreneurs and researchers in the sector of pharmaceutical and bioscience innovation in Greece. The competition is sponsored by a group of large pharmaceutical companies active in the Greek market (Abbvie, Pharmaserve-Lilly, MSD, Novartis, Roche, Pharmathen, Chiesi and Genesis). The competition aims at strengthening the business capabilities of small companies, entrepreneurs and researchers, with pioneering ideas and innovative proposals in the biosciences, pharmaceutical and healthcare sector, while promoting extroversion and the competitive presence of these emerging players in the international markets. Amyndas entered this 2-stage competition and won a prize for “Original Pharmaceutical Innovation”. In addition to the monetary award Amyndas is eligible to receive a range of supportive services, such as advice on small company development, on regulatory and clinical development, as well on raising funds, or gain access to training centers and R & D. For the original article in Greek, click here.
“Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The U.S. FDA orphan designation comes after the European Medicines Agency (EMA) orphan status approval of AMY-101 for the same indication, less than 2 months ago.”
ΒΗΜΑ Science, the science news source from Greek Sunday newspaper BHMA, on September 7, 2014, posted an extended and informative interview of Amyndas pharmaceuticals founder, Prof John Lambris. In this article, which aimed at communicating the results of Prof Lambris’ scientific research to the public, Amyndas’ promising new drugs and their potential therapeutic applications are presented for the first time in a widely-read national Greek newspaper, conveying the profound impact that these new therapies can have for patients and health care systems internationally. The article created significant interest, with its wide readers’ audience commending and responding enthusiastically, hoping that these new therapies to be brought to patients soon. The article can be accessed here.
EMA grants orphan drug designation for PNH to Amyndas Pharmaceuticals’ novel complement inhibitor. Amyndas Pharmaceuticals SA, the complement therapeutics company, announced that the European Medicines Agency (EMA) has granted AMY-101, a potent complement C3 inhibitor, an Orphan Drug Designation for the treatment of Paroxysmal Nocturnal Hemoglobinuria. – PR12364497
Amyndas features in BioWorld, the biopharmaceuticals news source from Thomson Reuters: Amyndas recent developments caught the interest of the international press, with BioWorld publishing an article about Amyndas on July 17. In this article, Amyndas is presented as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders, that could be more potent than other complement inhibitors. The article titled “Two- pronged Amyndas targets complement-based anti-inflammatories” can be accessed at: http://www.bioworld.com/content/two-pronged-amyndas-targets-complement-based-anti-inflammatories
University of Pennsylvania researchers have been searching for ways to prevent, halt and reverse periodontitis. In a report published in the Journal of Immunology, they describe a promising new target: a component of the immune system called complement. Treating monkeys with a complement inhibitor successfully prevented the inflammation and bone loss that is associated with periodontitis, making this a promising drug for treating humans with the disease.
A University of Pennsylvania research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States.
John Lambris, the Dr. Ralph and Sallie Weaver Professor of Research Medicine in the department of pathology and laboratory medicine at Penn’s Perelman School of Medicine, is part of an $8 million European Union FP7 grant, which has been awarded to a consortium of academic institutions and the biotech company called Amyndas Pharmaceuticals (based on Penn technology developed in the Lambris lab).
Almanac, Vol. 60, No. 19
On February 10, 2014 in the article entitled “Amyndas: Complement shutdown” Amyndas Pharmaceuticals is presented in BioCentury as an emerging company aiming to create novel therapeutics to treat complement-mediated disorders that could be more potent than other complement inhibitors.